- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02029053
Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness
VR101: A Pilot Study to Evaluate the Preliminary Feasibility and Safety of a Lubricating Intravaginal Ring to Relieve the Symptoms of Vaginal Dryness
This is a pilot study, assessing the ability and safety of the use of VR101 intravaginal ring to relieve the symptoms of vaginal dryness, in peri and post-menopausal women. VR1010 is designed to release glycerol. The study will assess the duration of lubrication/ moisturization of the vagina with the VR101 intravaginal ring in place (up to 7 days) and participant satisfaction of the device.
Study participants will insert the intravaginal ring and leave it in place for an initial 7 days and then repeat this process a 2nd time. Participants will respond to questionnaires, complete a daily diary and come in for 4 separate study visits. Each study visit will involve a brief vaginal exam.
Upon removal of the initially inserted device (7 days after first study visit), participants will insert a second device for an additional 7 days and undergo the same evaluation.
Study Overview
Status
Intervention / Treatment
Detailed Description
Vaginal dryness affects many women, although they frequently do not bring up the topic with their doctors. Vaginal dryness can dramatically affect women's lifestyle, in particular their sexual activity and relationship with their partner. Since we believe that living with uncomfortable vaginal dryness does not have to be part of aging, we intend to conduct this study to evaluate a lubricating vaginal ring developed to ease symptoms caused by vaginal dryness.
The objectives of this study are to obtain preliminary data on the ability of the VR101 intravaginal ring to relieve the symptoms of vaginal dryness in peri- and post-menopausal women. Effectiveness will be measured in two ways:
- Vaginal health index scoring assessed by a member of the research team
- Participant answers to questionnaires
Study objectives will assess the following:
- Successful placement of VR101 intravaginal ring into the vagina
- Ease of insertion and removal
- Comfort and fit
- Lubrication/ moisturization of the vagina
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Females over 35 years of age at the time of enrollment
- Willing to comply with study visit schedule
- Self-reported peri- or post-menopausal women with self-reported vaginal dryness
- Willing to abstain from vaginal intercourse while in the study
Exclusion Criteria:
- Use of hormone therapy
- Undergoing any vulvar or vaginal procedures (biopsies, radiation in the last 3 months)
- Active vulvar or vaginal injections/lesions or complaints, as well as undiagnosed abnormal genital bleeding
- History of chronic pelvic pain, interstitial cystitis, vulvar vestibulitis, pelvic inflammatory disease within the past 12 weeks
- Known current clinically evident cervical or vaginal infection
- Postpartum or post-abortion endometritis, unless symptoms resolved at least 12 weeks prior to study entry
- Current persistent, abnormal vaginal bleeding
- History of inability to place an IVR
- History of any abnormality of the vagina resulting in distortion of the vaginal canal or incompatible with IVR placement
- Body habitus, or history of lower genital tract abnormalities or prior surgeries, which may not allow the vagina to be appropriately accessed
- Known or suspected allergy or hypersensitivity to polyurethane or glycerol
- Known current alcohol or illicit drug abuse
- Participants who have not recovered from adverse events due to chemotherapy or radiation treatment for cancer
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Any condition that, in the opinion of the investigator or study staff that would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single Arm Study
Vaginal Lubrication Ring for Vaginal Dryness
|
Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits. Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later. The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring. The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam. Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal lubrication/moisturization
Time Frame: 14 days
|
Assessment of patient reported vaginal lubrication/moisturization while the intravaginal ring is inserted.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comfort and fit of intravaginal ring
Time Frame: 14 days
|
Assessment of patient satisfaction with the comfort and fit of the intravaginal ring during the study period.
|
14 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful vaginal placement and removal
Time Frame: 14 days
|
Assessment of patient ability to self-insert and self-remove the intravaginal ring at the initial study visit as well as throughout the 14 day time period of the study.
|
14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Margit Janat-Amsbury, MD, PhD, University of Utah
Publications and helpful links
General Publications
- Palacios S. Managing urogenital atrophy. Maturitas. 2009 Aug 20;63(4):315-8. doi: 10.1016/j.maturitas.2009.04.009. Epub 2009 Jun 2.
- Vaginal atrophy. Managing vaginal dryness and irritation. Mayo Clin Health Lett. 2012 Oct;30(10):6. No abstract available.
- Woods NF. An overview of chronic vaginal atrophy and options for symptom management. Nurs Womens Health. 2012 Dec;16(6):482-93; quiz 494. doi: 10.1111/j.1751-486X.2012.01776.x.
- Andelloux M. Products for sexual lubrication: understanding and addressing options with your patients. Nurs Womens Health. 2011 Jun-Jul;15(3):253-7. doi: 10.1111/j.1751-486X.2011.01642.x. No abstract available.
- Bond S, Horton LS. Management of postmenopausal vaginal symptoms in women. J Gerontol Nurs. 2010 Jul;36(7):3-7. doi: 10.3928/00989134-20100527-96. Epub 2010 Jul 8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 67709
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrophic Vaginitis
-
Fayoum UniversityRecruitingAtrophic Vaginitis | Postmenopausal Atrophic VaginitisEgypt
-
Amneal Pharmaceuticals, LLCCompletedAtrophic Vaginitis Due to MenopauseUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownAtrophic VaginitisChina
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAtrophic VaginitisUnited States
-
Alvogen Pine Brook LLCCompleted
-
Actavis Inc.Teva Pharmaceuticals USACompletedAtrophic VaginitisUnited States
-
Maire Mac BrideNational Center for Advancing Translational Sciences (NCATS)TerminatedAtrophic VaginitisUnited States
-
AGUNCO Obstetrics and Gynecology CentreCompletedAtrophic VaginitisItaly
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAtrophy | Vaginitis | Atrophic VaginitisUnited States, Canada
-
Izun Pharma LtdCompletedAtrophic VaginitisIsrael, United States
Clinical Trials on Vaginal Lubrication Ring for Vaginal Dryness
-
International Partnership for Microbicides, Inc.Completed
-
International Partnership for Microbicides, Inc.CompletedHuman Immunodeficiency VirusUnited States
-
Duramed ResearchCompletedOveractive BladderUnited States, Canada
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedHIV-1-infectionUnited States
-
International Partnership for Microbicides, Inc.Completed
-
University GhentCompleted
-
Evestra Inc.RecruitingContraception | Female | Healthy WomenCanada
-
International Partnership for Microbicides, Inc.CompletedHIV InfectionsSouth Africa, Uganda
-
International Partnership for Microbicides, Inc.Completed